BOSTON--(BUSINESS WIRE)--MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company, today announced the successful completion of an analytical validation study of its MenaCalc™ clinical test, which demonstrated strong overall assay performance and precision with mean coefficient of variation (%CV) of only 2.3% (Range 0.07-6.95). MenaCalc™ is a next generation driver-based prognostic test to predict the risk of developing cancer metastasis in patients with invasive breast cancer, squamous cell carcinoma of the lung and a number of additional epithelial-based cancer tumors. The MenaCalc™ results, reported as a MenaCalc™ Score, better inform physicians in making treatment decisions to enhance outcomes.
